Triamcinolone associated with few side effects

Article

Intravitreal triamcinolone acetonide (IVTA) for the treatment of steroid-responsive disorders of the posterior segment is associated with a low incidence of serious vision-threatening adverse events.

Intravitreal triamcinolone acetonide (IVTA) for the treatment of steroid-responsive disorders of the posterior segment is associated with a low incidence of serious vision-threatening adverse events, according to a report published in the January issue of Retina.

Daniel Roth of the Robert Wood Johnson Medical School, New Jersey, USA and colleagues retrospectively reviewed the medical records of 784 patients (929 consecutive eyes) who had received one or more IVTA injections for a steroid-responsive posterior segment disorder.

The most common adverse event occurring within three months of the initial injection was steroid-related ocular hypertension, with intraocular pressure spikes of >21 mmHg in 21% of eyes and >25 mmHg in 11% of eyes. Ocular inflammation was observed in six eyes (0.6%) and three eyes (0.3%) had corneal epithelial defects thought to be related to pretreatment with povidone-iodine solution. No eyes had culture-positive infectious endophthalmitis.

When administered under sterile conditions, concluded the authors, IVTA is associated with a low incidence of serious adverse events.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.